Table 2. The sensitivity, specificity and accuracy of the 3 miRNAs panel.
Training and validation set | Testing set | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Llung adenocarcinoma (82 cases) | Control (91controls) | Sensitivity | Specificity | Accuracy | Llung adenocarcinoma (36 cases) | Control (43controls) | sensitivity | specificity | accuracy | |
Plasma 3-miRNAs biomarker | 75 | 89 | 91.50% | 97.80% | 94.80% | 35 | 41 | 97.20% | 95.30% | 96.20% |
CEA | 26 | 90 | 31.70% | 98.90% | 67.10% | 8 | 43 | 22.20% | 100% | 64.60% |
CEA as the lung adenocarcinoma biomarker in three sets.